Walden Emil Bjørn-Yoshimoto

Dr. Walden Emil Bjørn-Yoshimoto

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Cell
Verified
Journal Article
Closed access
YPYao Peng
Yao Peng
JMJohn D. McCorvy
John D. McCorvy
KHKasper Harpsøe
Kasper Harpsøe
KLKatherine Lansu
Katherine Lansu
SYShuguang Yuan
Shuguang Yuan
ZLZhi-Jie Liu
Zhi-Jie Liu

1 February 2015 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
AJAnders A Jensen
Anders A Jensen
CFChristoph Fahlke
Christoph Fahlke
WBWalden Emil Bjørn-Yoshimoto
Walden Emil Bjørn-Yoshimoto
LBLennart Bunch
Lennart Bunch

1 September 2016 in Neurochemistry International
Verified
Journal Article
Closed access
WBWalden Emil Bjørn-Yoshimoto
Walden Emil Bjørn-Yoshimoto
SUSuzanne M. Underhill
Suzanne M. Underhill

1 August 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JEJacob Eriksen
Jacob Eriksen
WBWalden Emil Bjørn-Yoshimoto
Walden Emil Bjørn-Yoshimoto
TJTrine Nygaard Jørgensen
Trine Nygaard Jørgensen
ANAmy Hauck Newman
Amy Hauck Newman
UGUlrik Gether
Ulrik Gether
The dopamine transporter (DAT) mediates reuptake of released dopamine and is the target for psychostimulants, such as cocaine and amphetamine. DAT undergoes marked constitutive endocytosis, but little is known about the fate and sorting of the endocytosed transporter. To study DAT sorting in cells lines, we fused the one-transmembrane segment protein Tac to DAT, thereby generating a transporter (TacDAT) with an extracellular antibody epitope suited for trafficking studies. TacDAT was functional and endocytosed constitutively in HEK293 cells. According to an ELISA-based assay, TacDAT intracellular accumulation was increased by the lysosomal protease inhibitor leupeptin and by monensin, an inhibitor of lysosomal degradation and recycling. Monensin also reduced TacDAT surface expression consistent with partial recycling. In both HEK293 cells and in the dopaminergic cell line 1Rb3An27, constitutively internalized TacDAT displayed primary co-localization with the late endosomal marker Rab7, less co-localization with the "short loop" recycling marker Rab4, and little co-localization with the marker of "long loop" recycling endosomes, Rab11. Removal by mutation of N-terminal ubiquitination sites did not affect this sorting pattern. The sorting pattern was distinct from a bona fide recycling membrane protein, the beta(2)-adrenergic receptor, that co-localized primarily with Rab11 and Rab4. Constitutively internalized wild type DAT probed with the fluorescently tagged cocaine analogue JHC 1-64, exhibited the same co-localization pattern as TacDAT in 1Rb3An27 cells and in cultured midbrain dopaminergic neurons. We conclude that DAT is constitutively internalized and sorted in a ubiquitination-independent manner to late endosomes/lysosomes and in part to a Rab4 positive short loop recycling pathway.

22 July 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
WBWalden Emil Bjørn-Yoshimoto
Walden Emil Bjørn-Yoshimoto
IRIris Bea Ramiro
Iris Bea Ramiro
MYMark Yandell
Mark Yandell
JMJ Michael McIntosh
J Michael McIntosh
BOBaldomero Olivera
Baldomero Olivera
HSHelena Safavi-Hemami
Helena Safavi-Hemami
Conotoxins form a diverse group of peptide toxins found in the venom of predatory marine cone snails. Decades of conotoxin research have provided numerous measurable scientific and societal benefits. These include their use as a drug, diagnostic agent, drug leads, and research tools in neuroscience, pharmacology, biochemistry, structural biology, and molecular evolution. Human envenomations by cone snails are rare but can be fatal. Death by envenomation is likely caused by a small set of toxins that induce muscle paralysis of the diaphragm, resulting in respiratory arrest. The potency of these toxins led to concerns regarding the potential development and use of conotoxins as biological weapons. To address this, various regulatory measures have been introduced that limit the use and access of conotoxins within the research community. Some of these regulations apply to all of the ≈200,000 conotoxins predicted to exist in nature of which less than 0.05% are estimated to have any significant toxicity in humans. In this review we provide an overview of the many benefits of conotoxin research, and contrast these to the perceived biosecurity concerns of conotoxins and research thereof.

10 October 2016 in FEMS Yeast Research
Verified
Journal Article
Open access
PDF file
BLBeata Joanna Lehka
Beata Joanna Lehka
MEMichael Eichenberger
Michael Eichenberger
WBWalden Emil Bjørn-Yoshimoto
Walden Emil Bjørn-Yoshimoto
KVKatherina Garcia Vanegas
Katherina Garcia Vanegas
NBNicolaas Buijs
Nicolaas Buijs
MNMichael Naesby
Michael Naesby
Phenylpropanoids, such as flavonoids and stilbenoids, are of great commercial interest, and their production in Saccharomyces cerevisiae is a very promising strategy. However, to achieve commercially viable production, each step of the process must be optimised. We looked at carbon loss, known to occur in the heterologous flavonoid pathway in yeast, and identified an endogenous enzyme, the enoyl reductase Tsc13, which turned out to be responsible for the accumulation of phloretic acid via reduction of p-coumaroyl-CoA. Tsc13 is an essential enzyme involved in fatty acid synthesis and cannot be deleted. Hence, two approaches were adopted in an attempt to reduce the side activity without disrupting the natural function: site saturation mutagenesis identified a number of amino acid changes which slightly increased flavonoid production but without reducing the formation of the side product. Conversely, the complementation of TSC13 by a plant gene homologue essentially eliminated the unwanted side reaction, while retaining the productivity of phenylpropanoids in a simulated fed batch fermentation.